Activation of antioxidant pathways in ras-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry

Cancer Research

Volumn 64, Issue 13, 2004, Pages 4577-4584

  Young, Travis W ^a   Mei, Fang C ^a   Yang, Gong ^b   Thompson Lanza, Jennifer A ^b   Liu, Jinsong ^b   Cheng, Xiaodong ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAS PROTEIN; REACTIVE OXYGEN METABOLITE; TELOMERASE;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL TRANSFORMATION; ENZYME ACTIVE SITE; HUMAN; HUMAN CELL; MUTATION; NUCLEOTIDE SEQUENCE; ONCOGENE; OVARY CANCER; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN TARGETING; PROTEOMICS; SPECTROMETRY; TUMOR SUPPRESSOR GENE; TWO DIMENSIONAL ELECTROPHORESIS;

ANTIOXIDANTS; APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; FEMALE; HUMANS; HYDROGEN PEROXIDE; MASS SPECTROMETRY; OVARIAN NEOPLASMS; OVARY; OXIDATIVE STRESS; PROTEOMICS; RAS PROTEINS; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 3042739537     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0222     Document Type: Article

References (45)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999; 400:464-8.
3. Elenbaas B, Spirio L, Koerner F, et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 2001;15: 50-65.
4. Lundberg AS, Randell SH, Stewart SA, et al. Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene 2002;21: 4577-86.
5. Rich JN, Guo C, McLendon RE, Bigner DD, Wang XF, Counter CM. A genetically tractable model of human glioma formation. Cancer Res 2001;61:3556-60.
6. Yu J, Boyapati A, Rundell K. Critical role for SV40 small-t antigen in human cell transformation. Virology 2001;290:192-8.
7. Aunoble B, Sanches R, Didier E, Bignon YJ. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). Int J Oncol 2000;16:567-76.
8. Okamoto A, Sameshima Y, Yokoyama S, et al. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 1991;51:5171-6.
9. Li SB, Schwartz PE, Lee WH, Yang-Feng TL. Allele loss at the retinoblastoma locus in human ovarian cancer. J Natl Cancer Inst 1991;83:637-40.
10. Hashiguchi Y, Tsuda H, Yamamoto K, Inoue T, Ishiko O, Ogita S. Combined analysis of p53 and RB pathways in epithelial ovarian cancer. Hum Pathol 2001;32:988-96.
11. Wan M, Li WZ, Duggan BD, Felix JC, Zhao Y, Dubeau L. Telomerase activity in benign and malignant epithelial ovarian tumors. J Natl Cancer Inst 1997;89:437-41.
12. Kyo S, Kanaya T, Ishikawa H, Ueno H, Inoue M. Telomerase activity in gynecological tumors. Clin Cancer Res 1996;2:2023-8.
13. Wang ZR, Liu W, Smith ST, Parrish RS, Young SR. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH. Exp Mol Pathol 1999;66: 140-8.
14. Baker VV, Borst MP, Dixon D, Hatch KD, Shingleton HM, Miller D. c-myc amplification in ovarian cancer. Gynecol Oncol 1990;38:340-2.
15. Yuan ZQ, Sun M, Feldman RI, et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 2000;19:2324-30.
16. Sun M, Wang G, Paciga JE, et al. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 2001;159:431-7.
17. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
18. Mok SC, Bell DA, Knapp RC, et al. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 1993;53:1489-92.
19. Ichikawa Y, Nishida M, Suzuki H, et al. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res 1994;54:33-5.
20. Varras MN, Sourvinos G, Diakomanolis E, et al. Detection and clinical correlations of ras gene mutations in human ovarian tumors. Oncology 1999;56:89-96.
21. Singer G, Oldt R III, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003;95: 484-6.
22. Gemignani ML, Schlaerth AC, Bogomolniy F, et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 2003;90:378-81.
23. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
24. Patton SE, Martin ML, Nelsen LL, et al. Activation of the ras-mitogen-activated protein kinase pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines Cancer Res 1998;58:2253-9.
25. Liu J, Yang G, Thompson-Lanza JA, et al. A genetically defined model for human ovarian cancer. Cancer Res 2004;64:1655-63.
26. Blum H, Beier H, Gross HL. Improved silver staining of plant proteins. RNA and DNA in polyacrylamide gels. Electrophoresis 1987;8:93-9.
27. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996;68:850-8.
28. Gharahdaghi F, Weinberg CR, Meagher DA, Imai BS, Mische SM. Mass spectrometric identification of proteins from silver-stained polyacrylamide gel: a method for the removal of silver ions to enhance sensitivity. Electrophoresis 1999;20:601-5.
29. Lewis TS, Hunt JB, Aveline LD, et al. Identification of novel MAP kinase pathway signaling targets by functional proteomics and mass spectrometry. Mol Cell 2000;6: 1343-54.
30. Bernard K, Litman E, Fitzpatrick JL, et al. Functional proteomic analysis of melanoma progression. Cancer Res 2003;63:6716-6725.
31. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
32. Yang G, Thompson JA, Fang B, Liu J. Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumorgrowth in a model of human ovarian cancer. Oncogene 2003;22:5694-701.
33. Auersperg N, Siemens CH, Myrdal SE. Human ovarian surface epithelium in primary culture. In Vitro 1984;20:743-55.
34. Hancock JF, Paterson H, Marshall CJ. A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell 1990;63:133-9.
35. Staniek K, Gille L, Kozlov AV, Nohl H. Mitochondrial superoxide radical formation is controlled by electron bifurcation to the high and low potential pathways. Free Radic Res 2002;36:381-7.
36. Miranda-Vizuete A, Damdimopoulos AE, Spyrou G. The mitochondrial thioredoxin system. Antioxid Redox Signal 2000;2:801-10.
37. Kang SW, Chae HZ, Seo MS, Kim K, Baines IC, Rhee SG. Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha. J Biol Chem 1998;273:6297-302.
38. Pelicano H, Feng L, Zhou Y, et al. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem 2003;278:37832-9.
39. Wonsey DR, Zeller KI, Dang CV. The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. Proc Natl Acad Sci USA 2002;99:6649-54.
40. Choi JH, Kim TN, Kim S, et al. Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res 2002; 22:3331-5.
41. Nonn L, Berggren M, Powis G. Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol Cancer Res 2003;1:682-9.
42. Alsina B, Corominas M, Berry MJ, Baguna J, Serras F. Disruption of selenoprotein biosynthesis affects cell proliferation in the imaginal discs and brain of Drosophila melanogaster. J Cell Sci 1999;112:2875-84.
43. Behne D, Kyriakopoulos A. Mammalian selenium-containing proteins. Annu Rev Nutr 2001;21:453-73.
44. Toyokuni S, Okamoto K, Yodoi J, Hiai H. Persistent oxidative stress in cancer. FEBS Lett 1995;358:1-3.
45. Dreher D, Junod AF. Role of oxygen free radicals in cancer development. Eur J Cancer 1996;32A:30-8.